Endothelial cell activation by antiphospholipid antibodies is modulated by Krüppel-like transcription factors

Blood

Volumn 117, Issue 23, 2011, Pages 6383-6391

  Allen, Kristi L ^a   Hamik, Anne ^b   Jain, Mukesh K ^b   McCrae, Keith R ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 2; KRUPPEL LIKE FACTOR 4; PHOSPHOLIPID ANTIBODY; TRANSCRIPTION FACTOR RELA;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ACTIVATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENT ABORTION; THROMBOSIS;

EID: 79959441187     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-313072     Document Type: Article

References (51)

1. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost. 2003;1(5):931-942.
2. Galli M, Barbui T. Antiphospholipid antibodies and thrombosis: strength of association. Hematol J. 2003;4(3):180-186. (Pubitemid 36789972)
3. Rand JH. The antiphospholipid syndrome. Annu Rev Med. 2003;54:409-424. (Pubitemid 37386404)
4. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007; 109(2):422-430. (Pubitemid 46105935)
5. de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein Idependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrinolysis. 2008;19(8):757-764.
6. Lin WS, Chen PC, Yang CD, et al. Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum. 2007;56(5): 1638-1647.
7. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipids bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163(3):1193-1200. (Pubitemid 37040155)
8. Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood. 1994;83(9):2532-2540. (Pubitemid 24135845)
9. Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol. 2009;27(4):668-677.
10. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96(5): 2211-2219.
11. 2- glycoprotein I antibodies. Blood. 2005;105(5): 1964-1969. (Pubitemid 40731779)
12. 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000; 275(20):15541-15548. (Pubitemid 30337288)
13. Simantov R, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, Silverstein RL. Antiphospholipid antibodies activate vascular endothelial cells. Lupus. 1996;5(5):440-441. (Pubitemid 26354062)
14. 2-glycoprotein I antibodies. Thromb Haemost. 2002;88(5):851-857. (Pubitemid 35345346)
15. 2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor a and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007;56(8):2687-2697. (Pubitemid 47237287)
16. Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum. 2004; 50(9):2911-2919. (Pubitemid 39209530)
17. Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54(8):2558-2567. (Pubitemid 44205017)
18. 2 glycoprotein I for ApoER2α on platelets is located in domain V. J Biol Chem. 2005;280(44):36729-36736. (Pubitemid 41587752)
19. de Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20(11):E83-E88.
20. Montiel-Manzano G, Romay-Penabad Z, Papalardo de ME, et al. In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci. 2007;1108:540-553. (Pubitemid 47528768)
21. Pearson R, Fleetwood J, Eaton S, Crossley M, Bao S. Kruppel-like transcription factors: a functional family. Int J Biochem Cell Biol. 2008;40(10): 1996-2001. (Pubitemid 352004270)
22. Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res. 2007;100(12):1686-1695. (Pubitemid 46987860)
23. Lin Z, Kumar A, SenBanerjee S, et al. Kruppellike factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res. 2005;96(5):e48-e57.
24. SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med. 2004; 199(10):1305-1315. (Pubitemid 38685723)
25. Kumar A, Lin Z, SenBanerjee S, Jain MK. Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases. Mol Cell Biol. 2005;25(18): 5893-5903. (Pubitemid 40946546)
26. Hamik A, Lin Z, Kumar A, et al. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem. 2007;282(18):13769-13779. (Pubitemid 47100499)
27. Feinberg MW, Cao Z, Wara AK, Lebedeva MA, SenBanerjee S, Jain MK. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem. 2005;280(46):38247-38258. (Pubitemid 43853721)
28. 2-glycoprotein I antibody on factor Va degradation by activated protein C and its cofactor protein S. Am J Hematol. 1995;49(1):89-91.
29. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci U S A. 1979; 76(11):5674-5678. (Pubitemid 10168670)
30. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett. 2006;28(19):1601-1613. (Pubitemid 44306128)
31. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol. 1993;13(6):3301-3310. (Pubitemid 23157268)
32. Zeng M, Kumar A, Meng G, et al. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem. 2002; 277(47):45611-45618. (Pubitemid 36159172)
33. Ahmad N, Lingrel JB. Kruppel-like factor 2 transcriptional regulation involves heterogeneous nuclear ribonucleoproteins and acetyltransferases. Biochemistry. 2005;44(16):6276-6285. (Pubitemid 40570721)
34. Das H, Kumar A, Lin Z, et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A. 2006; 103(17):6653-6658.
35. Feinberg MW, Cao Z, Wara AK, et al. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem. 2005;280(46): 38247-38258. (Pubitemid 43853721)
36. Arad A, Proulle V, Furie RA, Furie BC, Furie B. β2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011;117(12):3453-3459.
37. Keeling DM, Wilson AJ, Mackie IJ, Isenberg DA, Machin SJ. Role of beta 2-glycoprotein I and antiphospholipid antibodies in activation of protein C in vitro. J Clin Pathol. 1993;46(10):908-911. (Pubitemid 23317669)
38. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004;91(4):667-673. (Pubitemid 38477445)
39. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with the lupus anticoagulant. J Clin Invest. 1999;104(1): 93-102. (Pubitemid 29534349)
40. Pericleous C, Giles I, Rahman A. Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? Lupus. 2009;18(8):671-675.
41. Kinev AV, Roubey RA. Tissue factor in the antiphospholipid syndrome. Lupus. 2008;17(10): 952-958.
42. Adams M. Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation. Semin Thromb Hemost. 2008;34(3):251-255.
43. Jy W, Tiede M, Bidot CJ, et al. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res. 2007;121(3):319-325.
44. Dekker RJ, Boon RA, Rondaij MG, et al. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood. 2006;107(11):4354-4363. (Pubitemid 43801361)
45. Dimitrova Y, Dunoyer-Geindre S, Reber G, Mach F, Kruithof EK, de Moerloose P. Effects of statins on adhesion molecule expression in endothelial cells. J Thromb Haemost. 2003;1(11):2290-2299.
46. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004;2(9):1558-1563. (Pubitemid 40186171)
47. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48(11): 3272-3279. (Pubitemid 37409342)
48. Rossi J, Rouleau L, Tardif JC, Leask RL. Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress. Life Sci. 2010;87(3):92-99.
49. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation. 2005;112(5):720-726. (Pubitemid 41099052)
50. Ohnesorge N, Viemann D, Schmidt N, et al. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). J Biol Chem. 2010;285(34):26199-26210.
51. Villarreal G Jr, Zhang Y, Larman HB, Gracia-Sancho J, Koo A, Garcia-Cardena G. Defining the regulation of KLF4 expression and its downstream transcriptional targets in vascular endothelial cells. Biochem Biophys Res Commun. 2010;391(1):984-989.